Korean Pharma Earnings Roundup: Companies Struggled In First Quarter Because of April Price Cuts And Tightened Regulatory Grip On Rebates
This article was originally published in PharmAsia News
Executive Summary
As widely expected, top Korean companies were badly hit during the first quarter by April price cuts and a continuing government crackdown on rebates.